glaucoma laser surgery headline image
 

horizontal bar

Glaucoma Research Links


No Rest Until They Find a Cure for Glaucoma | Health news for ...

Variation in Schlemm's Canal Diameter and Location by Ultrasound ...

Smart nanomaterial could lead to glaucoma breakthrough

Glaucoma Linked with Low Vitamin C - Progressive Health Blog

Blue Gene Supercomputer to join Australia's fight against glaucoma ...

<< 1 2 3 >>


A Patient's Guide to Glaucoma
A Patient's Guide to Glaucoma
by Young H Kwon John H Fingert Emily C Greenlee
Our Price: $16.15
Used from: $16.15

Shields' Textbook of Glaucoma (Allingham, Shields' Textbook of Glaucoma)
Shields' Textbook of Glaucoma (Allingham, Shields' Textbook of Glaucoma)

Our Price: $151.20
Used from: $18.71

Glaucoma-Patient to Patient-A Coping Guide for You and Your Family
Glaucoma-Patient to Patient-A Coping Guide for You and Your Family
by Edith Marks
Our Price: $26.95
Used from: $19.21

Cataract; Glaucoma and Other Eye Disorders : Prevention and Cure with Proven Natural Methods
Cataract; Glaucoma and Other Eye Disorders : Prevention and Cure with Proven Natural Methods
by Tobe; John H.
Used from: $1.98

Surgical Techniques in Ophthalmology Series: Glaucoma Surgery: Text with DVD
Surgical Techniques in Ophthalmology Series: Glaucoma Surgery: Text with DVD
by Teresa C. Chen MD FACS
Our Price: $116.80
Used from: $106.60

 

SLT Secrets Recommended Products


Glaucoma Research News

Sylentis Receives Authorization to Commence a New Phase I/II Clinical Trial with SYL040012 for Treating Elevated ...

- SYL040012 is a new compound arising from Sylentis' research in ophthalmological disorders. - It is indicated for treating ocular hypertension and preventing glaucoma. - SYL040012 is a form of interference RNA (RNAi). - It reduces intraocular pressure by inhibiting the expression of b-adrenergic receptors. MADRID, Sept. 7 /PRNewswire/ -- Sylentis, a biopharmaceutical subsidiary of Grupo Zeltia ...

Read more...


Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery. There currently are no approved ...

Read more...


Promedior Announces Publication of New Research Demonstrating Pentraxin-2/SAP is a Potent Inhibitor of Asthma and ...

MALVERN, Pa.--(BUSINESS WIRE)--Promedior announces publication of research in the Journal of Allergy and Clinical Immunology demonstrating pentraxin-2/SAP is a potent inhibitor of asthma and asthma-induced lung fibrosis.

Read more...


Stem Cell Ruling Halts Sight-Saving Research

The Association for Research in Vision and Ophthalmology (ARVO), a professional organization of member scientists, opposes the Federal District Court injunction that froze federal funding for human embryonic stem cell (hESC) research. ARVO is troubled by this barrier to research that has the potential to restore sight and mitigate eye damage. ARVO members investigate hESC therapies for treating ...

Read more...


Eyeing vitamins for peepers

Generations of kids have heard their parents tell them that carrots will help them see better. It turns out that research has now confirmed what Mom has always known: Certain nutrients – included those found in carrots - really do aid eye health.

Read more...


 
Home · Sitemap